iBet uBet web content aggregator. Adding the entire web to your favor.
iBet uBet web content aggregator. Adding the entire web to your favor.



Link to original content: http://pubmed.ncbi.nlm.nih.gov/17577801/
Bupropion and cognitive-behavioral treatment for depression in smoking cessation - PubMed Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2007 Jul;9(7):721-30.
doi: 10.1080/14622200701416955.

Bupropion and cognitive-behavioral treatment for depression in smoking cessation

Richard A Brown  1 , Raymond Niaura, Elizabeth E Lloyd-Richardson, David R Strong, Christopher W Kahler, Ana M Abrantes, David Abrams, Ivan W Miller
Affiliations
Randomized Controlled Trial

Bupropion and cognitive-behavioral treatment for depression in smoking cessation

Richard A Brown et al. Nicotine Tob Res. 2007 Jul.

Abstract

This study is a randomized, double-blind, placebo-controlled clinical trial examining the effects of an intensive cognitive-behavioral mood management treatment (CBTD) and of bupropion, both singularly and in combination, on smoking cessation in adult smokers. As an extension of our previous work, we planned to examine the synergistic effects of CBTD and bupropion on smoking cessation outcomes in general and among smokers with depression vulnerability factors. Participants were 524 smokers (47.5% female, M (age) = 44.27 years) who were randomized to one of four 12-week treatments: (a) standard, cognitive-behavioral smoking cessation treatment (ST) plus bupropion (BUP), (b) ST plus placebo (PLAC), (c) standard cessation treatment combined with cognitive-behavioral treatment for depression (CBTD) plus BUP, and (d) CBTD plus PLAC. Follow-up assessments were conducted 2, 6, and 12 months after treatment, and self-reported abstinence was verified biochemically. Consistent with previous studies, bupropion, in comparison with placebo, resulted in better smoking outcomes in both intensive group treatments. Adding CBTD to standard intensive group treatment did not result in improved smoking cessation outcomes. In addition, neither CBTD nor bupropion, either alone or in combination, was differentially effective for smokers with single-past-episode major depressive disorder (MDD), recurrent MDD, or elevated depressive symptoms. However, findings with regard to recurrent MDD and elevated depressive symptoms should be interpreted with caution given the low rate of recurrent MDD and the low level of depressive symptoms in our sample. An a priori test of treatment effects in smokers with these depression vulnerability factors is warranted in future clinical trials.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Participant enrollment. BUP, bupropion; CBTD, cognitive–behavioral therapy for depression; PLAC, placebo; ST, standard treatment.
Figure 2
Figure 2
Rates of confirmed 7-day point-prevalence abstinence at the end of the treatment period, as well as at 2, 6, and 12 months after treatment ended. BUP, bupropion; CBTD, cognitive–behavioral therapy for depression; PLAC, placebo; ST, standard treatment.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ahluwalia JS, Harris KJ, Catley D, Okuyemi KS, Mayo MS. Sustained-release bupropion for smoking cessation in African Americans: A randomized controlled trial. The Journal of the American Medical Association. 2002;288:468–474. - PubMed
    1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4. Washington, DC: Author; 1994.
    1. Anda RF, Williamson DF, Escobedo LG, Mast EE, Giovino GA, Remington PL. Depression and the dynamics of smoking: A national perspective. The Journal of the American Medical Association. 1990;264:1541–1545. - PubMed
    1. Brown RA, Kahler CW, Niaura R, Abrams DB, Sales SD, Ramsey SE, Goldstein MG, Burgess ES, Miller IW. Cognitive–behavioral treatment for depression in smoking cessation. Journal of Consulting and Clinical Psychology. 2001;69:471–480. - PMC - PubMed
    1. Cinciripini PM, Wetter DW, Fouladi RT, Blalock JA, Carter BL, Cinciripini LG, Baile WF. The effects of depressed mood on smoking cessation: Mediation by postcessation self-efficacy. Journal of Consulting and Clinical Psychology. 2003;71:292–301. - PubMed

Publication types

MeSH terms

Substances